Novartis AG
NVS Real Time Price USD$NVS is featured in our Shelley Moore Capito and Tom Carper strategies.
See All StrategiesRecent trades of NVS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by NVS's directors and management
Government lobbying spending instances
-
$40,000 Feb 04, 2003 Issue: Agriculture
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Enhanced antigen presenting ability of rna car t cells by co-introduction of costimulatory molecules Dec. 10, 2024
-
Patent Title: Heteroaromatic nmda receptor modulators and uses thereof Dec. 10, 2024
-
Patent Title: Automatic drug delivery device Dec. 10, 2024
-
Patent Title: Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b Dec. 10, 2024
-
Patent Title: Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof Dec. 03, 2024
-
Patent Title: Methods of treating dry eye disease using tnf alpha antagonists Nov. 19, 2024
-
Patent Title: N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b Nov. 19, 2024
-
Patent Title: Nlrp3 inflammasome inhibitors Nov. 12, 2024
-
Patent Title: Process of manufacture of a compound for inhibiting the activity of shp2, as well as products resulting from acid addition Nov. 12, 2024
-
Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Nov. 05, 2024
-
Patent Title: Hydroquinazoline derivatives for the treatment of a disease or disorder Oct. 29, 2024
-
Patent Title: 2-azaspiro[3.4]octane derivatives as m4 agonists Oct. 22, 2024
-
Patent Title: 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof Oct. 01, 2024
-
Patent Title: Rapamycin derivatives Sep. 17, 2024
-
Patent Title: Combination therapy Sep. 17, 2024
-
Patent Title: Crystalline forms of a tlr7/tlr8 inhibitor Sep. 10, 2024
-
Patent Title: Naphthyridinone derivatives for the treatment of a disease or disorder Sep. 10, 2024
-
Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Sep. 10, 2024
-
Patent Title: Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors Sep. 10, 2024
-
Patent Title: Antiviral 1,3-di-oxo-indene compounds Sep. 10, 2024
-
Patent Title: Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders Sep. 03, 2024
-
Patent Title: Polyomavirus neutralizing antibodies Sep. 03, 2024
-
Patent Title: 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza Aug. 27, 2024
-
Patent Title: Immunosuppressant formulations Aug. 27, 2024
-
Patent Title: Anti-cd40 antibodies for use in treatment of sjögren's syndrome Aug. 20, 2024
-
Patent Title: Ribociclib tablet Aug. 20, 2024
-
Patent Title: Anti-baffr antibody formulations and methods of use thereof Aug. 06, 2024
-
Patent Title: Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor Aug. 06, 2024
-
Patent Title: Stable protein solution formulation containing high concentration of an anti-vegf antibody Jul. 30, 2024
-
Patent Title: Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof Jul. 30, 2024
-
Patent Title: Syringe Jul. 30, 2024
-
Patent Title: Medical container with nfc antenna Jul. 23, 2024
-
Patent Title: Compositions and methods for immunooncology Jul. 16, 2024
-
Patent Title: Variant cd58 domains and uses thereof Jul. 16, 2024
-
Patent Title: Combination therapy Jul. 16, 2024
-
Patent Title: Compounds and compositions for the treatment of cryptosporidiosis Jun. 25, 2024
-
Patent Title: Pulmonary hypertension biomarker Jun. 18, 2024
-
Patent Title: Factor xi antibodies and methods of use Jun. 18, 2024
-
Patent Title: N-substituted tetrahydrothienopyridine derivatives and uses thereof Jun. 18, 2024
-
Patent Title: Therapeutic combinations comprising a c-raf inhibitor Jun. 18, 2024
-
Patent Title: Antibody-il2 engrafted proteins and methods of use in the treatment of cancer Jun. 11, 2024
-
Patent Title: Compositions and methods for selective protein degradation Jun. 04, 2024
-
Patent Title: Human mesothelin chimeric antigen receptors and uses thereof Jun. 04, 2024
-
Patent Title: Anti-cd48 antibodies, antibody drug conjugates, and uses thereof Jun. 04, 2024
-
Patent Title: Crystalline forms of potassium channel modulators May. 28, 2024
-
Patent Title: Crystalline forms of a lta4h inhibitor May. 28, 2024
-
Patent Title: Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies May. 21, 2024
-
Patent Title: Cd19 and cd22 chimeric antigen receptors and uses thereof May. 07, 2024
-
Patent Title: Tricyclic akr1c3 dependent kars inhibitors Apr. 30, 2024
-
Patent Title: Methods of treating hiv-haart induced partial lipodystrophy with fgf21 protein variant fc fusion proteins Apr. 23, 2024
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of NVS in WallStreetBets Daily Discussion
Recent insights relating to NVS
Recent picks made for NVS stock on CNBC
ETFs with the largest estimated holdings in NVS
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.